BOARD OF DIRECTORS
Dr. Robert Melamede, Ph.D. - President & CEO
Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. He retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he continues to teach. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabinoids, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede also serves on the Advisory Board of The Journal of the International Association for Cannabis as Medicine, and the Scientific Advisory Board Medical of the Marijuana Policy Advocacy Project, as well as the Scientific Advisory Board of Americans for Safe Access. He also served as a director of Newellink Inc, a Colorado-based company specializing in cancer research.
Chad S. Johnson - COO, General Counsel, and Director
Mr. Johnson, a native of Emporia, Kansas, and resident of Washington, D.C., began his professional career in 1992 after graduating from Harvard College and Harvard Law School. Following a federal judicial clerkship, Mr. Johnson joined the law firm Skadden Arps Slate Meagher & Flom LLP, where he practiced for several years in federal and state financial institution regulatory law with a focus on mergers and acquisitions, serving such clients as Citigroup, Sumitomo Bank, and Travelers. He also performed substantial pro bono work for national LGBT and HIV and AIDS organizations while at Skadden. In 2000, Mr. Johnson left his firm to serve as the Deputy Director of Business Leader Outreach and Deputy Director of Gay and Lesbian Issues for the Gore/Lieberman campaign, after which he served as Executive Director of the National Stonewall Democrats, the only national LGBT gay Democrats organization in the nation. From 2003 to 2012, Mr. Johnson served as chief of staff and general counsel of The Center for Cosmetic Surgery. In addition to other legal, charitable, and business endeavors, in 2010 Mr. Johnson co-founded the World AIDS Institute, a non-profit organization dedicated to document and preserve the global history of AIDS and to strengthen the spectrum of initiatives to find a cure, and more recently in 2012 co-founded with Timothy Ray Brown (the Berlin Patient) and David Purdy, the only charitable organization with a sole mission of finding an HIV cure: the Timothy Ray Brown Foundation. In 2013, Mr. Johnson was appointed to serve as a member of the board of directors, chief operating officer, and general counsel of The X-Change Corporation.
Richard Ogden, Ph.D. - Chief Scientific Officer
Dr. Ogden co-founded RORR Inc., a medical, scientific consulting and education company contracted by U.S. and European-based clients, including the International AIDS Society. RORR provides consulting for companies with a focus on viral infectious disease including HIV, Hepatitis C and respiratory viruses.
Beginning his prestigious career as a Post Graduate Chemist at Cambridge University, Dr. Ogden then held several positions at Agouron Pharmaceuticals including Principal Scientist/Manager, New Projects Research, and Director and Senior Director of Scientific Development. Dr. Ogden was also the Senior Director of Scientific Affairs, HIV US Medical at Pfizer Inc.
Dr. Ogden was a team member in the HIV project that led to the discovery and development of Nelfinavir (Viracept).
In working with Pfizer, he had an additional opportunity to work with the Pfizer Foundation in its support of the Academic Alliance and its efforts in Uganda, and with Corporate Philanthropy, in its support of the World Economic Forum and the Global Business Council.
Dr. Ogden received his bachelor's degree in natural sciences and doctorate in synthetic organic chemistry at Cambridge University. His academic career started with postdoctoral research studying RNA transcription and processing at the University of California, San Diego, following which he undertook independent research, funded by the National Science Foundation, in the area of protein and RNA structure-function relationships at the University of California, San Diego and the Agouron Institute.
Ronald Sekura, Ph.D. - Executive Vice President of Regulatory Affairs
Dr. Sekura held the position of Food and Drug Administration (FDA) Research Chemist, Center for Biologics Evaluation and Review as well as Chief of the Pharmaceutical and Regulatory Affairs Branch of the Division of AIDS at The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH). Dr. Sekura’s career in drug development regulatory affairs spans over two decades with extensive experience in governmental regulatory requirements as well as publicly traded biotechnology. Dr. Ronald Sekura is currently President of VivoNex LLC and Biotechnology Assessment Services, Inc.
Dr. Sekura held the position of Research Chemist at The National Institute of Child Health and Human Development (NICHD) at the NIH and the Center for Biologics Evaluation and Research (CBER). He received his Bachelor of Science and Master of Science in Biochemistry degrees at Pennsylvania State University and his Ph.D., at Cornell University. Dr. Sekura is the author of over sixty scientific publications.
Christopher Meenan MS, MBA - Executive Vice President of Product Research and Development
Mr. Meenan has over 20 years of biopharmaceutical experience beginning in 1991 with Unigene Laboratories as a molecular biologist working on both drug product development and manufacturing technology for the companies peptide therapeutic programs. Chris helped to create the company's patented recombinant production technologies, which have been used to support development of several peptide programs. He also worked in transferring manufacturing technologies to in house and external large-scale cGMP facilities. Christopher held several positions within the R&D unit at Unigene including Senior Scientist for Molecular Biology and Fermentation Development where he continued to advance the manufacturing capabilities of the company's biologic products and develop new biologic compounds for in-house development. After receiving an MBA in 2007 Chris moved into a Director role in business development establishing an out licensing program for the company's proprietary recombinant manufacturing and drug delivery technologies. Other duties included evaluation of external products for potential in licensing. Since leaving Unigene in 2011 Christopher has worked as a consultant for several companies in the areas of business and product development, drug delivery and CTM sourcing, to creation of a new corporate entity for vaccine research.
Mariel Selbovitz, MPH - Vice President of Research Program Development
Ms. Selbovitz is a graduate of the Johns Hopkins School of Public Health and Cornell University and serves as the Chair of the Cornell AIDS Clinical Trials Group Community Advisory Board. Mariel has authored 15 abstracts that have been presented at leading HIV/AIDS conferences around the world. Most recently, she had an oral presentation accepted for publication by Retrovirology on the effect of Probiotics on immunological presentation and preservation of viral-host restrictive factors of Th17 cells in HIV patients. She has also published a number of articles on HIV biomedical interventions and public policy issues, including on the challenges facing the HIV drug pipeline.
Along with basic wet and dry laboratory research coordination at Cannabis Science Ms. Selbovitz will assist in design of preclinical and early stage protocol development, facilitate collaborative research and development agreements, interaction with NIH Office of Technology Transfer, interface with government sponsored clinical research programs on an international scale, engage in pre-clinical CRO oversight and investigative site management. Ms. Selbovitz will also assist in regulatory affairs, abstract development and other efforts pertinent to the development of CS-TATI-1.
Robert Kane - Vice President of Investor Relations
Cannabis Science embraces Mr. Kane and his Kaneabis Brand. Each one of Mr. Kane's endeavors falls directly in line with Cannabis Science’s mission to be established as a viable pharmaceutical/nutraceutical business model and investment alternative for all investors. For over a decade Robert J. Kane worked for Stifel Nicolaus (NYSE: SF - News) as a registered representative. Today, Mr. Kane, along with Cannabis Science, will educate conservative Wall Street that Cannabis Science is a viable alternative investment opportunity that will also help improve the health of mankind.